Pulmotect Initiates Landmark Phase 2 Clinical Trial in Immunosuppressed Cancer Patients
HOUSTON, TX, UNITED STATES, July 8, 2025 / EINPresswire.com / -- Pulmotect, Inc., a privately held clinical-stage biotechnology company, today announced that it has begun dosing in their 100 patient Phase 2, double-blind, placebo controlled, clinical trial in immunosuppressed patients with hematologic malignancies. The trial is funded in part by an $8.9 million Product Development Research grant awarded by the Cancer Prevention and Research Institute of Texas ( CPRIT, ID#DP230066).
'This clinical trial is a key stepping stone in our development program with PUL-042. The three viruses that we are targeting have no effective treatments and are the most serious and potentially lethal viruses that cause pneumonia in this patient population. It is unheard of for an agent to be clinically effective against multiple different viruses however, PUL-042 activates lung surface immunity to fight off infection and is effective in multiple preclinical models against viruses, bacteria and fungi. The prospect of viral resistance to treatment is non-exsitent due to PUL-042 being a host directed therapy which makes this an exciting and potentially paradigm changing therapeutic. ' said Dr. Colin Broom, CEO of Pulmotect.
'This trial is an example of bringing private and public resources together to address a significant problem facing cancer patients. With funding support from the state of Texas, Fannin Partners and other investors we are able to conduct this trial with the participation of leading cancer centers across the country and their patients.' said Leo Linbeck III, Chairman, Pulmotect Board of Directors and Chairman, Fannin Partners.
The Phase 2 antiviral trial is entitled 'A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients with Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) with Documented Viral Infections with Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV).' (NCT06665100). The design of the trial builds upon the experience and results from Pulmotect's previous Phase 2 trials that demonstrated activity of inhaled PUL-042 against SARS-CoV-2 when administered by nebulization following diagnosis of viral infection.
About PUL-042
PUL-042, a first-in-class, synergistic combination of two toll-like receptor agonists, activates the lungs' surface innate immune system to inhibit and kill a wide range of respiratory pathogens. As microbes land on the epithelial cells of the lung lining, they are destroyed on contact by antimicrobial peptides and reactive oxygen species (ROS) that are released by epithelial cells. Activation of the innate immune system also triggers a response from the adaptive immune system. PUL-042 has demonstrated protection against a broad range of viral, bacterial and fungal respiratory pathogens in pre-clinical models, including models with immunocompromised animals. Phase 1 and 2 trials to date have demonstrated favorable tolerability in more than 200 subjects that included healthy individuals, COPD patients and subjects infected with SARS-CoV-2 with evidence of antiviral activity. PUL-042 may provide potentially life saving therapy for immunocompromised patients and also offer a broad-spectrum therapy for multiple other populations such as patients with COPD, asthma, seasonal infections and potential utility in future pandemics.
About Pulmotect
Pulmotect has an immunomodulatory platform technology and is developing PUL-042, a clinical-stage, first-in-class, inhaled, immunomodulatory agent. This synergistic agonist amplifies the innate immune defenses of the lung epithelial mucosa to provide broad-spectrum, pathogen-agnostic protection against respiratory infections. Invented at UT MD Anderson Cancer Center/Texas A&M University, PUL-042 has patents issued in 28 countries, both as a stand-alone composition of matter product and in combination with antivirals. PUL-042 R&D has been supported by the Department of Defense (DoD), National Institutes of Health (NIAID, NIGMS), CPRIT, other funding agencies, and private investors including Houston based Fannin Partners, LLC, a life sciences product development company. For more information, visit www.pulmotect.com.
Brenton Scott
Pulmotect, Inc.
+1 713-579-9226
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Why Oscar Health, Inc. (OSCR) Dipped More Than Broader Market Today
Oscar Health, Inc. (OSCR) closed the most recent trading day at $16.55, moving -1.55% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.07%. Meanwhile, the Dow experienced a drop of 0.37%, and the technology-dominated Nasdaq saw an increase of 0.03%. The company's stock has climbed by 13.89% in the past month, exceeding the Finance sector's gain of 2.38% and the S&P 500's gain of 3.94%. Market participants will be closely following the financial results of Oscar Health, Inc. in its upcoming release. The company is predicted to post an EPS of $0.34, indicating a 70% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.86 billion, up 28.96% from the year-ago period. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.61 per share and revenue of $11.21 billion. These totals would mark changes of +510% and +22.12%, respectively, from last year. Investors should also note any recent changes to analyst estimates for Oscar Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 11.11% downward. Right now, Oscar Health, Inc. possesses a Zacks Rank of #3 (Hold). In terms of valuation, Oscar Health, Inc. is presently being traded at a Forward P/E ratio of 27.41. This signifies a premium in comparison to the average Forward P/E of 9.99 for its industry. The Insurance - Multi line industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 145, placing it within the bottom 42% of over 250 industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow OSCR in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oscar Health, Inc. (OSCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Moon phase today: What the moon will look like on July 7, 2025
Ever wonder why the moon looks different every night? Well, that's because of a thing called the lunar cycle. This is a recurring series of eight unique phases of the moon's visibility. The whole cycle takes about 29.5 days (according to NASA), and these different phases happen as the Sun lights up different parts of the moon whilst it orbits Earth. The moon is always there, but what we see on Earth changes depending on how much it is lit up. See what's happening with the moon tonight, July 6. What is today's moon phase? As of Monday, July 7, the moon phase is Waxing Gibbous. From Earth, 89% of the moon will appear visible (according to NASA's Daily Moon Observation). This is the 12th day of the lunar cycle, and the moon is so close to being full. Some of the most notable things to spot with your bare eye tonight are the Aristarchus Plateau, the Mare Serenitatis, and the Mare Tranquillitatis. With binoculars, you'll also be able to catch a glimpse of the Posidonius Crater, the Alphonsus Crater, and the Clavius Crater. Add a telescope and you'll also spot Apollo 17, Fra Mauro Highlands, and Caucasus Mountains. When is the next full moon? This month's full moon will take place on July 10. The last full moon was on June 11. What are moon phases? Moon phases are caused by the 29.5-day cycle of the moon's orbit, which changes the angles between the Sun, Moon, and Earth. Moon phases are how the moon looks from Earth as it goes around us. We always see the same side of the moon, but how much of it is lit up by the Sun changes depending on where it is in its orbit. This is how we get full moons, half moons, and moons that appear completely invisible. There are eight main moon phases, and they follow a repeating cycle: New Moon - The moon is between Earth and the sun, so the side we see is dark (in other words, it's invisible to the eye). Waxing Crescent - A small sliver of light appears on the right side (Northern Hemisphere). First Quarter - Half of the moon is lit on the right side. It looks like a half-moon. Waxing Gibbous - More than half is lit up, but it's not quite full yet. Full Moon - The whole face of the moon is illuminated and fully visible. Waning Gibbous - The moon starts losing light on the right side. Last Quarter (or Third Quarter) - Another half-moon, but now the left side is lit. Waning Crescent - A thin sliver of light remains on the left side before going dark again.
Yahoo
an hour ago
- Yahoo
The One Thing You Should Never, Ever Do in the Hour After Eating Lunch, According to a Cardiologist
The One Thing You Should Never, Ever Do in the Hour After Eating Lunch, According to a Cardiologist originally appeared on Parade. No matter what your health goals are, you likely start each day with the best of intentions. You have a healthy breakfast, full of fiber and protein. You enjoy a cup of coffee, which is known to support both brain and heart health. Maybe you even go for a walk or get a workout in. But by the time afternoon hits, it's easy for healthy habits to fall by the wayside. There's too much to do and not enough time, which can lead to doing (and eating) what's most convenient, even if it isn't healthy. And there's one common afternoon habit, in particular, that a cardiologist wishes people wouldn't do because it's detrimental to heart health. 🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊 You're likely familiar with the afternoon slump. Typically, it happens about an hour after eating lunch. Blood sugar drops and tiredness sets in, making it hard to get through the rest of the day. To overcome it, many people turn to an energy drink. But Dr. Bhavna Suri, MD, a cardiologist with Manhattan Cardiology and contributor to LabFinder, wishes this habit would be left Suri explains that energy drinks can negatively impact heart health. 'Drinking these substances in excess sometimes speeds up our heart rate too much, or can cause some extra heartbeats, called ectopy,' she says, explaining that when this happens, it can lead to palpitations or a feeling of fluttering in the I'm a Cardiologist, and This 'Relaxing' Habit Is Actually Harming Your Heart Health Scientific research backs this up, showing that too much caffeine puts stress on the cardiovascular system, increasing the risk of arrhythmia. Other studies show that drinking energy drinks can cause blood pressure to go up. Drinking soda isn't any better. Scientific research shows that regularly drinking soda increases the risk of cardiovascular disease. Unfortunately, the same is true of diet soda. Another reason why Dr. Suri warns against using energy drinks to overcome an afternoon slump is because they can get in the way of getting a good night's sleep. Scientific research shows that not getting enough sleep on a regular basis increases the risk of cardiovascular disease. Related: Okay, so energy drinks and soda are out. What is a more heart-healthy way to get through the afternoon? Dr. Suri recommends taking a walk after lunch and getting some sunshine to help wake the body up. 'Incorporating a 15-minute walk [into your afternoon] can get blood circulating and can be good for your blood pressure and energy levels,' she says. Instead of downing an energy drink that can lead to heart palpitations, you'll be doing something that a wealth of scientific research has shown reduces the risk of cardiovascular Dr. Suri says that there's a way to craft your lunch in a way that will make experiencing an afternoon slump less likely. 'Having a protein-rich meal as opposed to high carbohydrates at lunch can improve energy levels,' she says. This is because simple carbs (like bread, chips, soda and pastries) increase blood sugar levels and then cause them to drop, which leads to a decrease in energy levels. But protein-based foods like chicken, tofu, beans and chickpeas don't spike blood sugar, which will keep energy levels more steady. Building an after-lunch walk into your daily routine is a way to keep your healthy habits going throughout the afternoon. By making a conscious effort to support your health in the morning and afternoon, you'll be more likely to keep it up in the evening too. Soon, your afternoon walk will become such an integral part of your routine that it will become automatic. And that's bound to benefit your heart both now and in the future. Up Next:Dr. Bhavna Suri, MD, a cardiologist with Manhattan Cardiology and contributor to LabFinder Effects of coffee/caffeine on brain health and disease: What should I tell my patients? Practical Neurology. 2016 Impact of Coffee Consumption on Cardiovascular Health. The Ochsner Journal. 2023 Effects of energy drinks on the cardiovascular system. World Journal of Cardiology. 2017 Energy Drink Consumption: Beneficial and Adverse Health Effects. International Journal of Health Sciences. 2015 The Impacts of Sugar-Sweetened Beverages (SSB) on Cardiovascular Health. Cureus. 2022 Diet Soft Drink Consumption is Associated with an Increased Risk of Vascular Events in the Northern Manhattan Study. Journal of General Internal Medicine. 2012 Sleep Duration as a Risk Factor for Cardiovascular Disease — a Review of the Recent Cardiovascular Reviews. 2010 Walking — the first steps in cardiovascular disease Opinion in Cardiology. 2011 The One Thing You Should Never, Ever Do in the Hour After Eating Lunch, According to a Cardiologist first appeared on Parade on Jul 8, 2025 This story was originally reported by Parade on Jul 8, 2025, where it first appeared.
